Cytosorbents Corp Stock Price, News & Analysis

CytoSorbents Corporation (NASDAQ: CTSO) presented new data on CytoSorb® at the 36th EACTS Annual Meeting in Milan, highlighting its effectiveness in cardiac surgery. The study involved 130 patients undergoing surgery for Staphylococcal aureus endocarditis. The results showed that CytoSorb significantly reduced postoperative vasopressor requirements (p<0.02) and sepsis-related mortality (8.0% vs. 21.8%, p=0.02). Furthermore, it demonstrated significant improvements in 30-day (17.3% vs. 32.7%, p=0.03) and 90-day mortality (21.3% vs. 40%, p=0.03), emphasizing its potential as a safe therapy in high-risk cardiac surgeries.

CytoSorbents Corporation (NASDAQ: CTSO) announced the upcoming retirement of CFO Kathleen P. Bloch on March 31, 2023, after a decade of service. Bloch will assist as a consultant post-retirement to ensure a smooth transition. Under her leadership, the company raised over $140 million and expanded globally, distributing products in 75 countries. CEO Phillip Chan praised her contributions, which included significant improvements in accounting and investor relations. The company aims for continued growth and FDA approval for its DrugSorb-ATR system.

CytoSorbents Corporation (NASDAQ: CTSO) has been awarded a three-year Phase III contract worth $4.3 million by the U.S. Army Medical Research Acquisition Activity. This contract aims to develop the HemoDefend-BGA™ filter for the creation of freeze-dried universal plasma, which could be rapidly deployed in emergency settings without the need for blood typing. The technology aims to greatly simplify logistics for both military and civilian responders, potentially saving lives during trauma care.

CytoSorbents Corporation (NASDAQ: CTSO) will present at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, from 2:30-2:55 PM EDT. CEO Dr. Phillip Chan will lead the presentation, and 1x1 meetings with management are available during the event. A live webcast will be accessible via the provided link, and an archived recording will be available on the Company’s website.

CytoSorbents Corporation (NASDAQ: CTSO) announced a $1,977,024 grant from the U.S. Army Medical Research Acquisition Activity to further develop its HemoDefend-BGA™ adsorber. This technology aims to create a universal plasma by removing anti-A and anti-B antibodies, potentially enhancing emergency treatments in critical care. The two-year grant will fund pre-clinical studies to evaluate safety and efficacy. This initiative supports a market estimated at $400 million to $600 million in westernized countries, addressing a significant need for plasma in civilian and military settings.

CytoSorbents Corporation (NASDAQ: CTSO) announced that CEO Phillip Chan will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. An on-demand webcast of the presentation will be available later, and company executives will hold one-on-one meetings with investors throughout the event. CytoSorbents specializes in blood purification for critical conditions and has 179,000 CytoSorb devices used globally. The company is also pursuing FDA approval for DrugSorb™-ATR, aimed at antithrombotic drug removal during surgeries.

CytoSorbents Corporation (NASDAQ: CTSO) has announced that the Turkish Ministry of Health will now cover the cost of treatment with its CytoSorb® product. This approval allows hospitals and doctors in Turkey to purchase CytoSorb directly without restrictions, marking a significant advancement in critical care treatment for patients with severe sepsis, septic shock, and those undergoing cardiothoracic surgery. The partnership with Bıçakcılar Medical Devices played a crucial role in achieving this reimbursement, enhancing patient access to this innovative blood purification therapy.

CytoSorbents Corporation (NASDAQ: CTSO) announced that the Israeli Ministry of Health has granted national reimbursement for its product CytoSorb® in specific cardiac surgery cases, effective 2023. This initiative acknowledges the device’s role in managing patients during emergency surgeries involving anticoagulants like ticagrelor and rivaroxaban. Approximately 4,000 heart surgeries occur annually in Israel, underscoring the relevance of this reimbursement. CytoSorbents is positioned to benefit from the growing demand for advanced medical technologies in Israel’s robust healthcare system.